After treating his own rare disease, Chasing My Cure author David Fajgenbaum explains how existing drugs can help other sufferers survive the unknown.
What We Discuss with David Fajgenbaum:
• Dr. David Fajgenbaum nearly died multiple times from a rare ailment called Castleman disease • , for which there was no effective treatment available.
• The current healthcare system does not incentivize pharmaceutical companies to find new uses for existing drugs • , especially for rare diseases, leaving many potential treatments undiscovered.
• Driven by his own experiences, Dr. Fajgenbaum realized that many existing FDA-approved drugs could be used to fight rare diseases • for which they weren't originally intended.
• Dr. Fajgenbaum founded Every Cure, a nonprofit organization that uses AI to match existing drugs with rare diseases they could potentially treat • , greatly accelerating the process of finding cures.
• You can make a positive impact by supporting organizations like Every Cure, which are working tirelessly to find treatments for rare diseases using innovative approaches. • Consider donating to their cause, spreading awareness about their mission, or even sharing your own experiences with off-label drug use that has helped you or someone you know. Every contribution, no matter how small, can help bring hope and relief to those suffering from rare diseases.
• And much more...
Full show notes and resources can be found here: jordanharbinger.com/1005
This Episode Is Brought To You By Our Fine Sponsors: jordanharbinger.com/deals
Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!
Like this show? Please leave us a review here — even one sentence helps! Consider including your Twitter handle so we can thank you personally!
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis
Dansk
Danmark